Skip to main content

autologous tumor infiltrating lymphocytes ln-145

Generic: Autologous Tumor Infiltrating Lymphocytes LN-145

autologous tumor infiltrating lymphocytes ln-145: 6 clinical trials tracked.

autologous tumor infiltrating lymphocytes ln-145 evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about autologous tumor infiltrating lymphocytes ln-145, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trials (6)

A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma

NCT07288073·Phase 2
Recruiting

Primary endpoint: Tumor-infiltrating lymphocyte (TIL) Production

Interventionalopen14 targetStarted 2026-02Completion 2029-061 site · United StatesKaram Khaddour, MD, MS

A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors

NCT06566092·Phase 1·IOVA
Active, not recruiting

Primary endpoint: Incidence rate of Treatment-Emergent Adverse Events

Interventionalopen40 targetStarted 2024-03Completion 2028-075 sites · United StatesIovance Biotherapeutics, Inc.

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103·Phase 2·IOVA
Recruiting

Primary endpoint: Objective Response Rate

Interventionalopen170 targetStarted 2021-05Completion 2031-1250 sites · Australia, Canada, France, Germany…Iovance Biotherapeutics, Inc.

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

NCT03645928·Phase 2·IOVA
Terminated

Primary endpoint: Objective Response Rate

Interventionalopen225 targetStarted 2019-05Completion 2026-0234 sites · Canada, Germany, Greece, Spain…Iovance Biotherapeutics, Inc.

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

NCT03449108·Phase 2
Active, not recruiting

Primary endpoint: Objective response rate

Interventionalopen30 targetStarted 2018-04Completion 2027-041 site · United StatesM.D. Anderson Cancer Center

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

NCT03108495·Phase 2·IOVA
Terminated

Primary endpoint: Cohort 1 and 2: Objective Response Rate

Interventionalopen210 enrolledStarted 2017-06Completion 2025-0843 sites · France, Germany, Italy, Netherlands…Iovance Biotherapeutics, Inc.